NLA 2026
By Buzzbox Media · Last reviewed August 3, 2026
What is NLA?
The only US conference dedicated to lipidology. If you sell lipid panel diagnostics, point-of-care cholesterol testing, or market lipid-lowering therapies, NLA is where the prescribers and clinical thought leaders gather. The lipid therapy market is booming with novel agents driving renewed interest.
What are the key facts about NLA?
- Host organization: National Lipid Association
- Primary specialty: lipidology
- Scale: mid
- Geography: US
- International attendance: ~10%
- See all Cardiology conferences
Which device categories fit NLA?
Which buyer stages does NLA fit?
What does NLA charge for booth space?
Cost not published
National Lipid Association does not publish booth pricing for NLA that we can link to, so we do not list a figure here. We would rather show nothing than an estimate you cannot check. Ask them directly on the NLA exhibitor page ↗.
Planning the NLA booth itself? Read our guide to medical conference booth design for booth types, union labor rules, and the corner upgrade.
Who attends NLA?
NLA has ~3,500 members. Scientific Sessions draws lipidologists, cardiologists, endocrinologists, and advanced practice providers focused on lipid management and cardiometabolic health. Growing attendance driven by PCSK9 inhibitors, bempedoic acid, and novel lipid therapies.
- Purchasing authority: ~55% of attendees
- Effective buyers: ~825
- International attendance: ~10%
Where is NLA held?
- Venue: Sheraton Grand Chicago Riverwalk, Chicago, IL
- Management company: NLA (in-house)
- Product theater: Available
Who else exhibits at NLA?
Exhibitor data coming soon for NLA.
Is NLA worth exhibiting?
Why Exhibit
The only US conference dedicated to lipidology. If you sell lipid panel diagnostics, point-of-care cholesterol testing, or market lipid-lowering therapies, NLA is where the prescribers and clinical thought leaders gather. The lipid therapy market is booming with novel agents driving renewed interest.
Why Skip
Small, niche audience. Device companies (vs. pharma/diagnostics) have limited relevance here. The exhibit hall is hotel-based and intimate, not a large trade show floor.
What should exhibitors know before NLA?
NLA is pharma-heavy on the exhibit floor. Device companies with lipid diagnostics or point-of-care testing fit well. Hotel-based show means lower logistics costs but limited booth sizes. Chicago Sheraton is a nice venue.
What is the Buzzbox Score for NLA?
7.2 / 10 (Strong)
7.2 out of 10. A solid, dependable show for the right exhibitor. The lightest dimension is data transparency (7.0, ). The only US conference dedicated to lipidology.
How we score
Six weighted factors, each scored on a 0 to 100 rubric then normalized to a 7.0 to 10.0 band. Every show on this list cleared a relevance bar to be included, so 7.0 is the floor; the number tells you how far the leaders pull ahead. A factor we cannot source is left unscored rather than estimated, and the overall score above was set before any figure behind it was withdrawn.
Solid (7.4): 55% purchasing authority.
Not scored on cost: this organizer publishes no booth price we can link to.
Solid (7.0): attendee purchasing-authority data published, and all-in cost estimate available.
Strong (8.4): society-run exhibits (in-house), non-union venue (simpler, cheaper move-in), and product theater / demo stage available.
Strong (8.0): solid exhibitor rationale, "who should skip" note included, and the flagship / largest show in its niche.
Solid (7.4): mid-size with room to grow.
When are the NLA exhibitor deadlines?
Detailed deadlines not yet published for NLA. Check the official site for the application window.
Frequently Asked Questions
How much does a booth cost at NLA?
NLA does not publish booth pricing we can link to, so we do not list a cost for this show. Rather than estimate one, we point you at the organizer's exhibitor page to request current rates directly.
How many people attend NLA?
NLA draws approximately 1,500 attendees. NLA has ~3,500 members. Scientific Sessions draws lipidologists, cardiologists, endocrinologists, and advanced practice providers focused on lipid management and cardiometabolic health. Growing attendance driven by PCSK9 inhibitors, bempedoic acid, and novel lipid therapies.
When and where is NLA 2026?
NLA 2026 takes place June 11-14, 2026. The venue is Sheraton Grand Chicago Riverwalk, Chicago, IL. National Lipid Association hosts the meeting.
How many NLA attendees have purchasing authority?
About 55% of NLA attendees hold purchasing authority, which works out to roughly 825 effective buyers out of approximately 1,500 attendees. Effective buyers multiplies total attendance by the share of attendees who hold purchasing authority. Both inputs are estimates drawn from organizer reporting and our own exhibitor research, so read the figure as directional rather than exact.
How does Buzzbox Media score NLA?
NLA carries a Buzzbox Score of 7.2 out of 10 (Strong), with one caveat on this record: cost efficiency is not scored, because National Lipid Association publishes no booth price we can link to, and the overall score was set before that figure was withdrawn. The factors still scored are audience quality, data transparency, exhibitor experience, editorial value, and growth trajectory. Each factor is scored on a 0 to 100 rubric then normalized to a 7.0 to 10.0 band, and every conference in our index cleared a relevance bar to be listed, so 7.0 is the floor. On this record the highest is exhibitor experience at 8.4 and the lowest is data transparency at 7.0.
What products are a good fit for NLA Scientific Sessions exhibitors?
NLA is best suited for lipid panel and point-of-care cholesterol testing devices, LDL apheresis systems, cardiovascular risk assessment tools, and companies targeting physicians who prescribe or manage lipid-lowering therapies including PCSK9 inhibitors and statins.
How large is the NLA conference compared to AHA or ACC?
NLA draws about 1,500 attendees compared to AHA's 17,000 or ACC's 18,000. Its value is in audience specificity: nearly every attendee focuses on lipid management, giving lipid-focused device companies a higher signal-to-noise ratio than larger cardiology shows.